Information Provided By: 
Fly News Breaks for September 26, 2016
ARRY
Sep 26, 2016 | 10:16 EDT
Piper Jaffray analyst Edward Tenthoff raised his price target on Array BioPharma shares to $10 from $7 after the company's Phase III trial in BRAF-mutant melanoma met its primary endpoint, saying he is not concerned that the drug combo "barely missed" the trial's secondary endpoint. The analyst, who keeps an Overweight rating on Array shares, reminds investors that the company could be looking at two approvals in the $1B melanoma market with binimetinib having a PDUFA date of June 30.
News For ARRY From the Last 2 Days
ARRY
Apr 24, 2024 | 11:02 EDT
Wells Fargo notes that a group of seven domestic solar product makers, including First Solar (FSLR), filed a petition to levy anti-dumping and countervailing duties on solar imports from Cambodia, Malaysia, Thailand and Vietnam, looking for duties ranging from 70.4% to 271.5%. The firm, which included the "important reminder" that "this is just a petition," says the uncertainty created by the petition is "incrementally positive" for First Solar and negative for Canadian Solar (CSIQ), Array Technologies (ARRY) and Nextracker (NXT).
